On Mar. 22, 2024, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents 12 years of age and older.

Pemgarda is authorized for individuals who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.